Programme

Contents

Programme at a glance 3
Symposia in detail 9
Parallel sessions in detail 13
Proffered paper sessions in detail 25
Workshops in detail 31
**Programme at a glance  Sunday**

14.20 – 14.30  
**Introduction from the Chair of the NCRI**  
Sir Kenneth Calman  
Chair, National Cancer Research Institute, UK

14.30 – 15.10  
**Molecular alterations that predict premalignancy in breast cancer**  
Thea Tlsty  
University of California, San Francisco, USA

15.10 – 15.50  
**Cancer research for cancer prevention: an international view**  
Chris Wild  
International Agency for Research on Cancer, Lyon, France

15.50 – 17.20  
**Poster Session A and Refreshment Break**

17.30 – 19.00  
**Cancer survivorship: a new challenge in delivering quality cancer care**  
Patricia Ganz  
University of California, Los Angeles, USA

From presence and understanding towards a richer dialogue with patients, carers and the public  
Derek Stewart  
National Cancer Research Institute Consumer Liaison Group, UK

**Performance**  
‘Sing for life’ choir  
Tenovus, UK

19.00 – 21:00  
**Opening Reception and Trade Exhibition**
Programme at a glance Monday

08.00 – 08.40  Workshop
BACR educational workshop: Opening the vaults of industry
Steve Wedge
AstraZeneca, UK

08.45 – 09.00  Introduction to the programme
Tim Maughan
Cardiff University (Chair of the Programme Committee), UK

09.00 – 09.40  Ovarian cancer in 2010: are we making progress at last?
Stan Kaye
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK

09.40 – 10.20  Genome to systems biology in cancer medicine
Edison Liu
Genome Institute of Singapore, Singapore

10.20 – 11.00  Refreshment Break and Exhibition Viewing

11.00 – 12.30  Symposia
- Early diagnosis of cancer
  Hosted by Rebecca Fitzgerald
  University of Cambridge, UK
- Pathway-specific therapeutics
  Hosted by Richard Marais
  The Institute of Cancer Research, London, UK
- Stem cells and cancer
  Hosted by Tariq Enver
  UCL Cancer Institute, UK

12.30 – 14.20  Poster Session B and lunch

12.30 – 15.30  Trade Exhibition Viewing

13.00 – 14.00  Commercial workshop
- Illumina® high throughput sequencing – investigations into cancer genome biology

14.00 – 15.30  Proffered paper sessions
- Epidemiology and prevention
- The cancer cell and model systems
- Tumour specific research
14.00 – 15.30  Workshops

- Consumers and the research cycle
- ECMC workshop: development of a standardised approach to imaging tumour vasculature in clinical trials
- Linking healthcare data sets for research I: unlocking the potential for new areas of research through the NIHR Research Capability Programme
- TNM debate

15.40 – 17.10  Parallel sessions

- Anticancer drug discovery and medicinal chemistry
- Biology, epidemiology and prevention of HPV-induced malignancy
- Colorectal cancer
- Development and cancer: what does one teach us about the other?
- Genome stability and DNA repair
- Melanoma
- Putting evidence-based policy into practice
- The application of complementary therapies in cancer care

17.10 – 17.40  Refreshment Break

17.40 – 19.00  Clinical trials showcase

- Results on ICON7: A phase III randomised two-arm versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC).
  
  **Timothy Perren**
  St James’s University Hospital, Leeds, UK, presented on behalf of the GCIG ICON7 collaborators

- Results BC2001: a 2x2 phase III randomised trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone and standard (sRT) versus reduced high-dose volume RT (rvRT) in muscle invasive bladder cancer (MIBC) (CRUK/01/004)
  
  **Nicholas James**
  University of Birmingham, UK

- The MRC Myeloma IX Trial: beneficial effects of thalidomide and zoledronic acid for newly diagnosed myeloma patients of all ages
  
  **Tony Child**
  University of Leeds, UK

- Intergroup randomised controlled phase III trial of androgen deprivation therapy (ADT) +/- radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC, INT: T94-0110; NCT00002633)
  
  **Malcolm Mason**
  Cardiff University and Velindre Hospital, UK

19.00 – 21.00  Drinks Reception and canapés

20.00 – 22.30  Chairman’s Reception (by invitation)
Programme at a glance Tuesday

08.00 – 08.40  Workshop
BACR educational workshop: Drug development – metabolism as a generic target
_**Klaus Pors**_
Institute of Cancer Therapeutics, Bradford, UK

09.45 – 09.25  The hallmarks of cancer, revisited
_**Douglas Hanahan**_
The Swiss Institute for Experimental Cancer Research and the Swiss Federal Institute of Technology Lausanne, Switzerland

09.25 – 10.05  The epithelial-mesenchymal transition and the stem-cell state
_**Robert Weinberg**_
Whitehead Institute for Biomedical Research, Massachusetts, USA

10.05 – 10.20  Q & A session

10.20 – 11.00  Refreshment Break and Exhibition Viewing

11.00 – 12.30  Symposia
- **Biomarkers and imaging**
  _**Hosted by Caroline Dive**_
  Paterson Institute for Cancer Research, Manchester, UK
- **Hard to beat cancers: when can we expect progress?**
  _**Hosted by Herbie Newell**_
  Northern Institute for Cancer Research, University of Newcastle, UK
- **Teenagers and young adults**
  _**Hosted by Jeremy Whelan**_
  University College London, UK
- **Tumour microenvironment and inflammation**
  _**Hosted by Frances Balkwill**_
  Barts and The London School of Medicine and Dentistry,

12.30 – 14.20  Poster Session C and Lunch

12.30 – 15.30  Trade Exhibition Viewing

13.00 – 14.00  Commercial workshop
- Next generation sequencing to accelerate cancer studies

14.00 – 15.30  Workshops
- Cancer research networks collaborating with industry
- Holistic
- Linking healthcare data sets for research II: making use of linked cancer data through the National Cancer Data Repository
14.00 – 15.30  Proffered paper sessions
- Diagnosis and therapy
- Information, patients and the public / Survivorship and end-of-life care
- Tumour specific research: gastrointestinal

15.40 – 17.10  Parallel sessions
- Breast cancer
- Growth factors and cancer
- How to educate the general public about cancer research
- MicroRNAs in cancer
- Optimising local disease control: the potential impact of implementing new technologies and novel agents
- Paediatric cancers
- Smoking cessation: evidence-based policy
- Survivorship

17.10 – 17.40  Refreshment Break

17.40 – 18.20  Combining molecularly targeted therapies with chemoradiation
Ted Lawrence
University of Michigan, USA

18.20 – 19.00  Changing cancer mortality
Sir Richard Peto
University of Oxford, UK

19.00 Onwards  Pfizer/BOA Excellence in Oncology Awards (by invitation)

19.45 Onwards  Conference Dinner and Party
# Programme at a glance Wednesday

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00 – 09.40</td>
<td>Clinical research and healthcare outcomes</td>
</tr>
</tbody>
</table>
|            | **Peter Selby**  
St James’s University Hospital, Leeds, UK                           |
| 09.40 – 10.10 | Refreshment Break                                                   |
| 10.10 – 11.40 | Parallel sessions                                                   |
|            | • Breathlessness                                                   |
|            | • Chemokine ligands and receptors                                   |
|            | • Computational biology and pathway modelling                       |
|            | • Current issues in translational cancer research                    |
|            | • Environmental carcinogens                                         |
|            | • Head and neck cancer                                             |
|            | • Patient involvement in decision-making and choice                 |
|            | • Renal cancer                                                     |
| 11.50 – 12.30 | Of mice and women: how studying breast development informs us about breast cancer |
|            | **Zena Werb**  
University of California, San Francisco, USA                        |
| 12.30 – 12.40 | Closing comments                                                   |
|            | **Sir Kenneth Calman**  
Chair, National Cancer Research Institute, UK                        |
| 12.40 – 13.10 | Lunch (available to take away)                                     |
Symposia in detail Monday

Early diagnosis of cancer
Hosted by Rebecca Fitzgerald,
University of Cambridge, UK

- Introduction
  Rebecca Fitzgerald
  University of Cambridge, UK

- Cancer as acute disease
  Frede Olesen
  University of Aarhus, Denmark

- MDCT volume measurement as a diagnostic tool in lung cancer screening
  Matthijs Oudkerk
  BCN / University of Groningen, The Netherlands

- Minichromosome maintenance proteins in cancer screening
  Nick Coleman
  MRC Cancer Cell Unit, Cambridge, UK

Pathway-specific therapeutics
Hosted by Richard Marais,
The Institute of Cancer Research, London, UK

- Introduction
  Richard Marais
  The Institute of Cancer Research, London, UK

- The biology and therapeutic implications of BRAF and RAS signalling in cancer
  Richard Marais
  The Institute of Cancer Research, London, UK

- Cellular responses to DNA damage: new molecular insights and new opportunities for cancer therapy
  Stephen Jackson
  Wellcome Trust/Cancer Research UK Gurdon Institute, University of Cambridge, UK

- A chemical-genetic approach to melanocyte stem cells: a novel role for the Prl-3 phosphatase
  Elizabeth Patton
  Edinburgh Cancer Research Centre, UK
Stem cells and cancer
Hosted by Tariq Enver
UCL Cancer Institute, London, UK

- Introduction
  Tariq Enver,
  UCL Cancer Institute, London, UK

- Deciphering the mammary epithelial cell hierarchy
  John Stingl
  Cancer Research UK Cambridge Research Institute, UK

- Generation of leukaemia cell hierarchies by MLL fusion oncogenes
  Tim Somervaille
  Paterson Institute for Cancer Research, Manchester, UK

- Phenotypic heterogeneity and instability of human ovarian tumour-initiating cells
  Ben Neel
  Ontario Cancer Institute, Toronto, Canada
Symposia in detail **Tuesday**

**Biomarkers and imaging**

*Hosted by Caroline Dive*

Paterson Institute for Cancer Research, Manchester, UK

- **Introduction**
  Caroline Dive  
  Paterson Institute for Cancer Research, Manchester, UK

- **John Heymach**
  The University of Texas MD Anderson Cancer Center, Houston, USA

- **Circulating tumour cells**
  Johann de Bono  
  The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK

- **Imaging biomarkers for drug development**
  Ambros Beer  
  Ludwig-Maximilians-Universität, Munich, Germany

**Hard to beat cancers: when can we expect progress?**

*Hosted by Herbie Newell*

Northern Institute for Cancer Research, University of Newcastle, UK

- **Introduction**
  Herbie Newell  
  Northern Institute for Cancer Research, University of Newcastle, UK

- **Personalised therapy for lung cancer**
  Scott Gettinger  
  Yale University, Connecticut, USA

- **Incorporating targeted therapy into oesophagogastric cancer management**
  David Cunningham  
  The Royal Marsden NHS Foundation Trust, London and Surrey, UK

- **Developing pancreatic cancer medicines**
  David Tuveson  
  Cancer Research UK Cambridge Research Institute, UK
Teenagers and young adults
Hosted by Jeremy Whelan
University College London, UK

- Introduction
  Jeremy Whelan
  University College London, UK

- An analysis of factors affecting survival in adolescents and young adults with cancer
  David Thomas
  Peter MacCallum Cancer Centre, Melbourne, Australia

- What use are clinical trials to young people? Lessons from UK trial accrual 2005-2009
  Jeremy Whelan
  University College London, UK

- Specialist services for TYA with cancer: how do they contribute to better outcomes
  Faith Gibson
  Great Ormond St Hospital and London South Bank University, London, UK

- Setting the research agenda with young people
  NCRI Teenage and Young Adult Core Consumer Group
  National Cancer Research Institute, London, UK

Tumour microenvironment and inflammation
Hosted by Frances Balkwill
Barts and The London School of Medicine and Dentistry, UK

- Introduction
  Frances Balkwill
  Barts and The London School of Medicine and Dentistry, UK

- Sex, fat and infections: the molecular pathogenesis of hepatocellular carcinoma and inflammation linked cancer
  Michael Karin
  University of California, San Diego, USA

- Inflammation induced liver cancer: a lymphotoxin driven pathway to hepatocellular carcinoma
  Mathias Heinkenwälder
  University Hospital Zurich, Switzerland

- Mechanisms of stromal cell recruitment
  Robert Weinberg
  Whitehead Institute for Biomedical Research, Massachusetts, USA
Parallel sessions in detail Monday

**Anticancer drug discovery and medicinal chemistry**
Hosted by Roger Griffin
Northern Institute for Cancer Research, Newcastle, UK

- Introduction
  Roger Griffin
  Northern Institute for Cancer Research, Newcastle, UK

- Hypoxia-activated prodrugs for cancer therapy: progress towards an elusive goal
  William Denny
  University of Auckland, New Zealand

- The design of kinase inhibitors as anticancer compounds
  Kevin Foote
  AstraZeneca, UK

- Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction
  Ian Hardcastle,
  University of Newcastle, UK

**Biology, epidemiology and prevention of HPV-induced malignancy**
Hosted by Clare Wilkinson
University of Cardiff, UK

- Introduction
  Clare Wilkinson
  University of Cardiff, UK

- Matti Lehtinen
  University of Tampere, Finland

- Novel concepts in cervical cancer prevention: HPV screening and vaccination
  Xavier Bosch
  Institut Catala d’Oncologia, Barcelona, Spain

- Prevention of HPV-induced malignancy: now and in the future
  Peter Sasieni
  Queen Mary University of London, UK
Colorectal cancer
Hosted by Will Steward
Leicester Royal Infirmary, UK

- Introduction
  Will Steward
  Leicester Royal Infirmary, UK

- Howard McLeod
  The University of North Carolina, USA

- Tailoring adjuvant therapy to appropriate patient groups
  Jim Cassidy
  University of Glasgow, UK

- Towards personalisation in the management of metastatic in colorectal cancer
  Eric van Cutsem
  University of Leuven, Belgium

Development and cancer: what does one teach us about the other?
Hosted by Mariann Bienz
MRC Laboratory of Molecular Biology, Cambridge, UK

- Introduction
  Mariann Bienz
  MRC Laboratory of Molecular Biology, Cambridge, UK

- Drosophila as a model system for epithelial tumourigenesis
  Barry Thompson
  Cancer Research UK London Research Institute, UK

- Stem cell niche interactions in cancer formation and metastasis
  Joerg Huelsken
  Swiss Federal University of Technology Lausanne (EPFL), Switzerland

- Targeting the Hedgehog pathway in cancer
  Fred de Sauvage
  Genentech Inc, San Francisco, USA
**Genome stability and DNA repair**
Hosted by Stephen Jackson
Wellcome Trust/Cancer Research UK Gurdon, Institute, University of Cambridge, UK

- **Introduction**
  Stephen Jackson  
  Wellcome Trust/Cancer Research UK Gurdon Institute, University of Cambridge, UK

- Targeting DNA damage signalling and repair (DDR) for cancer therapy  
  Nicola Curtin  
  University of Newcastle, UK

- DNA damage response: mechanisms and relevance for human cancer  
  Jiri Bartek  
  Danish Cancer Society, Copenhagen, Denmark

- Understanding and targeting homologous recombination repair in cancer  
  Thomas Helleday  
  Gray Institute for Radiation Oncology and Biology, Oxford, UK

**Melanoma**
Hosted by Paul Lorigan  
University of Manchester, UK

- **Introduction**
  Paul Lorigan  
  University of Manchester, UK

- BRAF: melanoma’s first point of vulnerability  
  Keith Flaherty  
  Massachusetts General Hospital, Boston, USA

- Ulrich Keilholz  
  Charite, Berlin, Germany

- Genetic and environmental determinants of outcome from melanoma  
  Julia Newton-Bishop  
  University of Leeds, UK
Putting evidence-based policy into practice
Hosted by Sir Mike Richards
National Cancer Director (England), UK

- Introduction
  Sir Mike Richards
  National Cancer Director (England), UK

- Sir Mike Richards
  National Cancer Director (England), UK

- Translating best evidence into policy
  David Currow
  Cancer Institute NSW, Alexandria, Australia

- Putting evidence-based policy into practice: the Ontario, Canada experience
  Terrence Sullivan
  Cancer Care Ontario and University of Toronto, Canada

The application of complementary therapies in cancer care
Hosted by Andrew Ritchie
Basildon University Hospital, UK

- Introduction
  Andrew Ritchie
  Basildon University Hospital, UK

- Integrative oncology in the US: clinical delivery and unique research
  Moshe Frenkel
  Integrative Oncology Consultants, Zichron Yaacov, Israel

- Evidence-based practice: experience of integrating complementary therapies into the cancer service at The Royal Marsden NHS Foundation Trust
  Jeannie Dyer
  The Royal Marsden NHS Foundation Trust, London, UK

- Complementary medicine and cancer: an overview of integrated approaches
  George Lewith
  University of Southampton, UK
Parallel sessions in detail Tuesday

Breast cancer
Hosted by Alastair Thompson
University of Dundee, UK

- Introduction
  Alastair Thompson
  University of Dundee, UK

- Practical aspects of translational research in breast cancer
  Colin Purdie
  Ninewells Hospital, Dundee, UK

- Developing combination therapy approaches to advanced breast cancer – the role of translational research
  Ingunn Holen
  University of Sheffield, UK

- Targeting multiple pathways in ER+ve breast cancer to overcome resistance and improve clinical outcomes
  Stephen Johnston
  The Royal Marsden NHS Foundation Trust, London, UK

Growth factors and cancer
Hosted by Caroline Hill
Cancer Research UK London Research Institute, UK

- Introduction
  Caroline Hill
  Cancer Research UK London Research Institute, UK

- Intravital imaging of signalling pathway activity during cancer metastasis
  Erik Sahai
  Cancer Research UK London Research Institute, UK

- Ras signalling in health and disease
  Dafna Bar-Sagi
  New York University, USA

- Oncogenic signalling networks: relevance to therapy and to biomarker development
  Yosef Yarden
  Weizmann Institute of Science, Rehovoth, Israel
How to educate the general public about cancer research
Hosted by David Ardron
National Cancer Research Institute Consumer Liaison Group, UK

- Introduction
  David Ardron
  National Cancer Research Institute Consumer Liaison Group, UK

- Cancer: kill and cure
  Lawrence McGinty
  Independent Television News, London, UK

- The truth about cancer
  Richard Evans
  World Cancer Research Fund, London, UK

- Vivienne Parry
  University College London, UK

MicroRNAs in cancer
Hosted by Carlos Caldas
Cancer Research UK Cambridge Research Institute, UK

- Introduction
  Carlos Caldas
  Cancer Research UK Cambridge Research Institute, UK

- Dynamic regulation of microRNAs by growth factors: implications for tumour progression
  Yosef Yarden
  Weizmann Institute of Science, Rehovoth, Israel

- The miR-17~92 family of microRNA clusters in cancer and development
  Andrea Ventura
  Memorial Sloan-Kettering Cancer Center, New York, USA

- Post-transcriptional control of tumour suppressor miRNAs
  Andres Ramos
  MRC National Institute for Medical Research, London, UK
Optimising local disease control: the potential impact of implementing new technologies and novel agents
Hosted by Tim Illidge¹ and Richard Sainsbury²
¹University of Manchester, UK; ²British Oncological Association, UK

- Introduction
  Tim Illidge¹ and Richard Sainsbury²
  ¹University of Manchester, UK; ²British Oncological Association, UK

- The challenges of evaluating proton therapy in clinical trials
  Stephen Hahn
  University of Pennsylvania, Philadelphia, USA

- Biological and physical optimisation of radiotherapy for lung cancer
  Dirk de Ruysscher
  Maastricht University Medical Center, The Netherlands

- Optimising local disease control: how can we get more from radiotherapy?
  Kevin Harrington
  The Institute of Cancer Research, London, UK

Paediatric cancers
Hosted by Pam Kearns
University of Birmingham, UK

- Introduction
  Pam Kearns
  University of Birmingham, UK

- Gilles Vassal
  Institute Gustav Roussy, Paris, France

- The development of molecular targeted therapies for refractory paediatric malignancies
  Michelle Haber
  Children's Cancer Institute, Sydney, Australia

- Drug disposition and clinical pharmacology studies in children with cancer
  Gareth Veal
  Northern Institute for Cancer Research, University of Newcastle, UK
Smoking cessation: evidence-based policy
Hosted by Robert West
University College London, UK

- Introduction
  Robert West
  University College London, UK

- What can governments do to promote smoking cessation?
  Michael Cummings
  Roswell Park Cancer Institute, New York, USA

- Clinical interventions for smoking cessation
  Robert West
  University College London, UK

- Minimising harm from smoking in the individual and society
  Karl Fagerström
  Fagerström Consulting, Helsingborg, Sweden

Survivorship
Hosted by Jessica Corner
Macmillan Cancer Support, UK

- Introduction
  Jessica Corner
  Macmillan Cancer Support, UK

- Cancer survivorship care plans: what are they and why do we need them?
  Patricia Ganz
  University of California, Los Angeles, USA

- Building the evidence to inform service development for people making the transition to living life beyond cancer treatment
  Alison Richardson
  University of Southampton, UK

- Complementary medicine and cancer: an overview of integrated approaches
  Cathy Bradley
  Virginia Commonwealth University, Richmond, USA
Parallel sessions in detail **Wednesday**

**Breathlessness**
*Hosted by Irene Higginson*
King’s College London, UK

- **Introduction**
  *Irene Higginson*  
  King’s College London, UK

- **Overview of research into non-pharmacological interventions to relieve intractable breathlessness**
  *Claudia Bausewein*  
  King’s College London, UK

- **Amy Abernethy**  
  Duke University, North Carolina, USA

- **Breathlessness training for people with intrathoracic malignancy: a feasibility study comparing two training programmes**
  *Miriam Johnson*  
  The Hull York Medical School, Hull, UK

**Chemokine ligands and receptors**
*Hosted by Gerry Graham*
University of Glasgow, UK

- **Introduction**
  *Gerry Graham*  
  University of Glasgow, UK

- **Chemokine receptors and chemokine scavengers in mouse models of inflammation-driven tumourigenesis**
  *Rob Nibbs*  
  University of Glasgow, UK

- **Role of chemokines and their receptors in cancer metastasis**
  *Albert Zlotnik*  
  University of California, Irvine, USA

- **Improving cancer immunotherapy by preventing chemokine nitration**
  *Barbara Molon,*  
  Istituto Oncologico Veneto, Padova, Italy
Computational biology and pathway modelling
Hosted by John Heath
University of Birmingham, UK

- Introduction
  John Heath
  University of Birmingham, UK

- Dynamic regulation of growth factor receptor signalling networks
  Jason Haugh
  North Carolina State University, Raleigh, USA

- Executable strategies for cellular decision making
  Jasmin Fisher
  Microsoft Research, Cambridge, UK

- Experimental and computational analysis of the NF-kappa B signalling system
  Michael White
  University of Liverpool, UK

Current issues in translational cancer research
Hosted by Mitch Dowsett
The Institute of Cancer Research, London, UK

- Introduction
  Mitch Dowsett
  The Institute of Cancer Research, London, UK

- Jorge Reis-Filho
  The Institute of Cancer Research, London, UK

- Major statistical design and analysis issues for correlative research
  Lisa McShane
  National Cancer Institute, Bethesda, USA

- Cancer genomics and drug sensitivity: separating the wheat from the chaff
  Ultan McDermott
  Wellcome Trust Sanger Institute, Cambridge, UK
Environmental carcinogens
Hosted by Stephen Palmer
Cardiff University, UK

- Introduction
  Stephen Palmer
  Cardiff University, UK

- Mobile phone use and brain tumours: a review of the epidemiological evidence
  Maria Feychting
  Karolinska Institute, Stockholm, Sweden

- Risk of cancer from computed tomography (CT) examinations
  Rebecca Smith-Bindman
  University of California, San Francisco, USA

- Lung cancer and radon
  Sarah Darby
  University of Oxford, UK

Head and neck cancer
Hosted by Chris Nutting
The Royal Marsden NHS Foundation Trust, Sutton, UK

- Introduction
  Chris Nutting
  The Royal Marsden NHS Foundation Trust, Sutton, UK

- HPV in the oropharynx: what we know, and what we need to know
  Ned Powell
  Cardiff University, UK

- IMRT for head and neck cancer: promises and pitfalls
  David Rosenthal
  MD Anderson Cancer Center, Houston, USA

- Recent advances in chemoradiation for head and neck cancer
  Jean Bourhis
  Gustave Roussy Institute, Villejuif, France
Patient involvement in decision-making and choice
Hosted by Lesley Fallowfield
University of Sussex, UK

- Introduction
  Lesley Fallowfield
  University of Sussex, UK

- Patient preferences for control in treatment decision making: an international perspective
  Lesley Degner
  University of Manitoba, Winnipeg, Canada

- Barriers and drivers to shared decision-making
  Angela Coulter
  Foundation for Informed Medical Decision Making, Boston, USA

- Effective written communication to underpin patients’ decisions
  Peter Knapp
  University of Leeds, UK

Renal cancer
Hosted by Tim Eisen
University of Cambridge, UK

- Introduction
  Tim Eisen
  University of Cambridge, UK

- Renal cancer: molecular advances
  Eamonn Maher
  University of Birmingham, UK

- Surgical advances in renal cancer: 2010
  Inderbir Gill
  University of Southern California, USA

- Medical advances in renal cancer
  Cora Sternberg
  San Camillo Forlanini Hospital, Rome, Italy
Proffered paper sessions Monday

Epidemiology and prevention
Hosted by Rosalind Eeles
The Institute of Cancer Research, Sutton, UK

- Identification of a SNP in the KLK3 gene which predisposes to prostate cancer - the first coding SNP to be discovered in this disease
  Rosalind Eeles
  The Institute of Cancer Research, Sutton, UK

- Gene-environment interactions and breast cancer: prospective evidence from 7610 women with breast cancer in a large UK cohort
  Ruth Travis
  University of Oxford, UK

- 'Why it's not for us': the views of parents and girls in the UK who declined the HPV vaccination - a qualitative study
  Alison Clements
  University of Oxford, UK

- A validation study of genes and polymorphisms associated with radiation toxicity: preliminary results of the RAPPER study
  Gillian Barnett
  Strangeways Research Laboratory, Cambridge, UK

- Early results of the RCGP/NCAT national audit of cancer diagnosis in primary care
  Sean McPhail
  National Cancer Intelligence Network, London, UK

- Defining and measuring key timepoints and intervals in early diagnosis research: outcomes of a consensus working group
  David Weller
  University of Edinburgh, UK

- Hormone replacement therapy, oral bisphosphonates and risk of gastrointestinal cancer
  Jane Green
  University of Oxford, UK

- Insulin-like growth factors (IGFs) and IGF binding proteins in PSA-detected prostate cancer: a large population-based case-control study
  Mari-Anne Rowland
  University of Bristol, UK
The cancer cell and model systems
Hosted by Julian Downward
Cancer Research UK London Research Institute, UK

- MYC-dependent regulation and prognostic role of MYC stabilising protein, CIP2A, in human gastric cancer
  Anchit Khanna
  University of Tampere and Tampere University Hospital, Finland

- Polycomb-mediated regulation of the INK4/ARF tumour suppressor locus
  Emma Anderton
  Cancer Research UK London Research Institute, UK

- Fbw7 regulates intestinal cell lineage commitment and is a haploinsufficient suppressor of intestinal tumourigenesis
  Rocio Sancho
  Cancer Research UK London Research Institute, UK

- FUS/TLS is a novel mediator of androgen-dependent cell cycle progression and prostate cancer growth
  Greg Brooke
  Imperial College London, UK

- Regulators of mitotic transition determine paclitaxel resistance in vitro and predict poor prognosis in breast cancer in vivo
  Rebecca Burrell
  Cancer Research UK London Research Institute, UK

- An inducible caspase-3 ‘tumour death switch’ model to identify and quantify circulating biomarkers of apoptotic cell death using iTRAQ isobaric tags and mass spectrometry
  Kathryn Simpson
  Paterson Institute for Cancer Research, University of Manchester, UK

- ACP McElwain Prize: P-Rex1 is a central component of metastasis in malignant melanoma
  Colin Lindsay
  Beatson Institute for Cancer Research, Glasgow, UK

- BACR AstraZeneca Young Scientist Frank Rose Award: HNRNPUL-1 promotes DNA double-strand break end resection
  Grant Stewart
  University of Birmingham, UK
Tumour specific research
Hosted by Owen Sansom
Beatson Institute for Cancer Research, Glasgow, UK

- Genotypic profiling of 452 choroidal melanomas with Multiplex Ligation-Dependent Probe Amplification (MLPA) suggests crescendo malignancy
  **Bertil Damato**
  University of Liverpool, UK

- CARMA3 shRNA induces cisplatin sensitivity in ovarian cancer cells
  **Jiyuan Sun**
  The University of Texas MD Anderson Cancer Center, Houston, USA

- The prognostic significance of androgen receptor phosphorylation in prostate cancer
  **Si Jie Heng**
  University of Glasgow, UK

- Targeting c20orf20 for cutaneous squamous cell carcinoma therapy
  **Andrew South**
  University of Dundee, UK

- Functional characterisation of SET8 in prostate cancer cell lines
  **Dhuha Alkharafi**
  University of Newcastle, UK

- Targeted intra-operative radiotherapy (TARGIT) for early stage breast cancer: the TARGIT-A trial at 10 years maximum follow up
  **Jayant Vaidya**
  University College London, UK

- Functional evaluation of the homologous recombination pathway in epithelial ovarian cancer and the potential for targeted chemotherapy with PARP inhibitors
  **Asima Mukhopadhyay**
  Northern Institute for Cancer Research, University of Newcastle, UK

- MGMT methylation is strongly associated with and may precede IDH1/IDH2 mutations in adult astrocytic and oligodendrogial tumours
  **Shani Mulholland**
  University of Cambridge, UK
Proffered paper sessions Tuesday

**Diagnosis and therapy**
Hosted by Chris Boshoff
University College London, UK

- Discovery of new pathways and mechanisms of Notch signalling in angiogenesis
  Esther Bridges
  Weatherall Institute of Molecular Medicine, University of Oxford, UK

- Targeting Notch in pancreatic cancer
  Natalie Cook
  Cancer Research UK Cambridge Research Institute, UK

- Integration of miRNA and mRNA expression profiles in breast cancer identifies miRNA associated pathways and prognostic markers
  Francesca Buffa
  Weatherall Institute of Molecular Medicine, University of Oxford, UK

- Chemo- and radio-sensitisation of hepatocellular carcinoma by the DNA-dependent protein kinase inhibitor NU7441
  Joanne Munck
  Northern Institute for Cancer Research, University of Newcastle, UK

- Evaluation of a novel Ataxia telangiectasia mutated (ATM) and Rad3-related (ATR) inhibitor, NU6027
  Gary Beale
  University of Newcastle, UK

- Induction of a tumour-promoting phenotype in human macrophages by necrotic debris: role of TLR4 and p38 MAP kinase
  Russell Hughes
  Academic Unit of Inflammation and Tumour Targeting, Sheffield, UK

- Discovery of novel Pin1 inhibitors by structure-guided fragment evolution that downregulate cyclin D1 expression in PC-3 prostate cancer cells
  Jonathan Moore
  Vernalis, Cambridge, UK

- BACR Translational Research Award: Molecular taxonomy of breast cancer: is there a gold standard?
  Britta Weigelt
  Cancer Research UK London Research Institute, London, UK
What reasons do patients give for declining or participating in early phase cancer trials?

Susan Catt
CR-UK Psychosocial Oncology Group, Brighton and Sussex Medical School, UK

Physical activity intervention in cancer survivors: a systematic review and meta-analysis of randomised controlled trials

Judy Ho
University of Hong Kong, Hong Kong

The prognosis in palliative care study (PiPS)

Bridget Gwilliam
University of London, UK

Which research priorities are defined by young people with cancer – second consultation by the National Cancer Research Institute’s Teenage and Young Adult Core Consumer Group

Lorna Fern
University College Hospitals, London, UK

Cancer death data as part of the National End of Life Care Intelligence Network Website

Andy Pring
South West Public Health Observatory, Bristol, UK

Survival after first course of palliative radiotherapy: an observational cohort study

Matt Williams
Mount Vernon Cancer Centre, London, UK

Four-fold increase in recruitment of cancer patients to NCRN portfolio studies between 2001 and 2010: a tale of investment bringing returns

David Cameron
University of Edinburgh, UK

The primary health and supportive care needs of long-term cancer survivors

Sian Harrison,
University of Oxford, UK
**Tumour specific research: gastrointestinal**

**Hosted by David Cunningham**

The Royal Marsden NHS Foundation Trust, London and Surrey, UK

- Clinical development of catumaxomab (Removab) in malignant ascites
  **Simon Parsons**
  Nottingham City Hospital, UK

- Capecitabine/oxaliplatin vs. 5FU/oxaliplatin combination chemotherapy in advanced colorectal cancer (aCRC): the MRC COIN trial experience
  **Ayman Madi**
  Freeman Hospital, Newcastle upon Tyne, UK

-Mismatch repair status in stage II colorectal cancer: substantially reduced recurrence rate in mismatch repair deficient tumours supports routine testing
  **Gordon Hutchins**
  Leeds Institute of Molecular Medicine, UK

- A novel colorectal cancer susceptibility SNP in the EIF3H promoter influences patient survival and response to treatment
  **Christopher Smith**
  Cardiff University, UK

- Integrated analysis of genome-wide copy number and expression changes reveals novel genes in oesophageal adenocarcinoma
  **Xin Yi Goh**
  Hutchison-MRC Research Centre, Cambridge, UK

- Comparison of loss of MLH1 and MSH2 expression between oesophageal cancer and other sporadic cancers of the gastrointestinal tract – relationship with survival in 1027 cases
  **Imran Inam**
  Leeds Institute of Molecular Medicine, UK

- Porfimer sodium photodynamic therapy (PDT) plus stenting versus stenting alone in patients (pts) with advanced or metastatic cholangiocarcinomas and other biliary tract tumours (BTC): a randomised phase III study (Photostent-02)
  **Stephen P Pereira**
  University College London, UK

- Thirty-day post-operative mortality after colorectal cancer surgery in England
  **Eva Morris**
  University of Leeds, UK
Workshops in detail Monday

**BACR educational workshop: Opening the vaults of industry**  
Hosted by Steve Wedge  
AstraZeneca, UK

**Illumina® high throughput sequencing: investigations into cancer genome biology**  
Hosted by Richard Henfrey  
Illumina, Europe

**ECMC workshop: development of a standardised approach to imaging tumour vasculature in clinical trials**  
Hosted by Martin Leach  
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, UK

- **Introduction**  
  **Martin Leach**  
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK

- **Use of MRI for tumour vasculature quantification and validation in clinical trials**  
  **Martin Leach**  
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK

- **Use of PET/SPECT for tumour vasculature quantification and validation in clinical trials**  
  **Fiona Gilbert**  
  Aberdeen Biomedical Imaging Centre, University of Aberdeen, UK

- **Use of CT for tumour vasculature quantification and validation in clinical trials**  
  **Vicky Goh**  
  Mount Vernon Hospital, Northwood, UK

- **Use of ultrasound for tumour vasculature quantification and validation in clinical trials**  
  **Edward Leen**  
  Imperial College London, Hammersmith Hospital, UK

**Consumers and the research cycle**  
Hosted by David Ardron  
National Cancer Research Institute Consumer Liaison Group, UK
Linking healthcare data sets for research I: unlocking the potential for new areas of research through the NIHR Research Capability
Hosted by Sir Alex Markham
University of Leeds, UK

TNM debate
Hosted by Sir Mike Richards
National Cancer Director (England), UK
Workshops in detail Tuesday

**BACR educational workshop: Drug development – metabolism as a generic target**
Hosted by Klaus Pors
Institute of Cancer Therapeutics, Bradford, UK

- Exploiting drug metabolism in cancer drug discovery
  Klaus Pors
  Institute of Cancer Therapeutics, Bradford, UK

- Investigation of drug metabolism by cytochromes P450 in phase I studies
  Alan Boddy
  Northern Institute for Cancer Research, University the Newcastle, UK

**Next generation sequencing to accelerate cancer studies**
Hosted by Life Technologies, UK

**Cancer research networks collaborating with industry**
Hosted by Richard Kaplan¹ and Altaf Moledina²,
¹University of Leeds, UK; ²Chair of the NCRI Industry Consultation Group, UK and Pfizer, UK

- **Chris Wilks**
  AZ Clinical Project Co-ordination Director, AstraZeneca, UK
  - Overview of AstraZeneca and academia collaborations
  - Advantages of working with networks
  - Why delivery is important to both partners
  - Future opportunities – where we’d like to be

- **Ruth Plummer**
  Northern Institute for Cancer Research, Newcastle University, UK
  - Phase I trials

- **Richard Wilson**
  Centre for Cancer Research and Cell Biology, Queen’s University, Belfast, UK
  - Phase II and III trials
Holistic care
Hosted by Derek Stewart
National Cancer Research Institute Consumer Liaison Group, UK

- Holistic care from diagnosis – a personal journey
  April Matthews
  NCRI Consumer Liaison Group, UK

- Laura Lee
  Maggie’s Cancer Care Centres, UK

- Holistic Common Assessment in cancer outpatient clinics
  Penny Wright
  Leeds Psychosocial Oncology and Clinical Practice Research Group, UK

Linking healthcare data sets for research II: making use of linked cancer data through the National Cancer Data Repository
Hosted by Sir Alex Markham
University of Leeds, UK